Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 12/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | PDE4A | P27815 | 2/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.62 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.62 |
| ▸ | PDE2A | O00408 | 1/20 | 0.59 |
| ▸ | PDE1A | P54750 | 1/20 | 0.59 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.59 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.59 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.56 |
| ▸ | APP | P05067 | 2/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4924574 | 0.89 | PDE5A (0.72) | PDE5AMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL7503857 | 0.87 | PDE5A (0.69) | PDE5AMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL13192094 | 0.85 | PDE5A (0.67) | PDE5AMEN1ALDH1A1KMT2AAPP | |
| SCHEMBL7502657 | 0.84 | PDE4A (0.65) | PDE5AMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL7496663 | 0.84 | PDE5A (0.71) | PDE5AMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL7492651 | 0.84 | PDE5A (0.66) | PDE5AMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL7492948 | 0.84 | PDE5A (0.66) | PDE5AMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL7495616 | 0.84 | PDE4A (0.67) | PDE5AMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL8015499 | 0.84 | PDE5A (0.66) | PDE5AMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL8019648 | 0.83 | PDE4A (0.63) | PDE5AMEN1ALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0607439-B1 | NITROGENOUS HETEROCYCLIC COMPOUND | EISAI CO LTD (JP) | 2002-01-09 | — | — | EP | disclosed |
| US-20010031760-A1 | Method of treating a patient having precancerous lesions with quinazoline derivatives | PAMUKCU RIFAT (US) | 2001-10-18 | — | — | US | disclosed |
| US-6262059-B1 | Method of treating a patient having precancerous lesions with quinazoline derivatives | CELL PATHWAYS, INC. | 2001-07-17 | — | — | US | disclosed |
| US-5801180-A | ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | EISAI CO., LTD. (JP) | 1998-09-01 | — | — | US | disclosed |
| US-5693652-A | Benzimidazoles for ischemic heart conditions | EISAI CO., LTD. (JP) | 1997-12-02 | — | — | US | disclosed |
| US-5576322-A | Anti-ischemic 2,4-diaminoquinazolines | EISAI CO., LTD. (JP) | 1996-11-19 | — | — | US | disclosed |
| EP-0607439-A1 | NITROGENOUS HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 1994-07-27 | — | — | EP | disclosed |
| CN-1071164-A | Nitrogen-containing heterocycle compound | EISAI CO LTD (JP) | 1993-04-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031760-A1 | Method of treating a patient having precancerous lesions with quinazoline derivatives | MKI67, PCNA, NQO2 | PDE5A 2260/4885MEN1 340/4885ALDH1A1 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.